← Leaderboards
Salman R Khetani
University Of Illinois At Chicago
$7,662,172
Attributed
$12,322,824
Total exposure
17
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,109,780 · 15
FDA$213,044 · 2
By mechanism
R01$7,423,739 · 4
R21$3,448,055 · 8
RC1$910,000 · 1
R03$327,986 · 2
R44$113,044 · 1
R43$100,000 · 1
Top collaborators
- Gregory H Underhill10 shared
- Dawood Darbar6 shared
- Kostandin Pajcini3 shared
- Nancy L Allbritton2 shared
- Ramille N Shah2 shared
- Almudena Veiga-Lopez2 shared
- Steven A Weinman2 shared
- Brian Thomas Layden1 shared
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Dawood Darbar$15,920,976
- Almudena Veiga-Lopez$4,505,540
- Oliver Yu$1,994,729
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsPhenotypeHepatocyteEngineeringIn VitroLiverCoculture TechniquesIn VivoCell TypeResponseExtracellular MatrixPharmaceutical PreparationsInvestigationHepatic Stellate CellPhysiologicalHepaticEndothelial CellsPathway InteractionsMicrofluidicsTissuesFutureDrug MetabolismKupffer Cells3-Dimensional
Grant awards (43)
Synergistic effects of ECM and heterotypic crosstalk on cellular responses in non-alcoholic fatty liver disease$571,118
R01 · FY2025 · DK · contact PI
Engineering In Vitro Models of Pregnancy-Induced Liver Changes$440,908
R21 · FY2025 · HD · contact PI
Engineered culture platforms to uncover synergies between microenvironmental cues in modulating liver zonation$348,718
R01 · FY2025 · DK · contact PI
A Human Gut-Liver Platform with Microbiome Interactions for In Vitro Toxicology$197,126
R21 · FY2025 · ES · contact PI
Development of a 3D hepatic-placental tandem organ-on-a-chip for toxicological screening$195,102
R21 · FY2025 · ES · contact PI
Synergistic effects of ECM and heterotypic crosstalk on cellular responses in non-alcoholic fatty liver disease$559,114
R01 · FY2024 · DK · contact PI
Engineered culture platforms to uncover synergies between microenvironmental cues in modulating liver zonation$348,484
R01 · FY2024 · DK · contact PI
A Human Gut-Liver Platform with Microbiome Interactions for In Vitro Toxicology$251,525
R21 · FY2024 · ES · contact PI
Development of a 3D hepatic-placental tandem organ-on-a-chip for toxicological screening$239,850
R21 · FY2024 · ES · contact PI
Multicellular Organotypic Mouse Model of Alcoholic Liver Disease$189,094
R21 · FY2024 · AA · contact PI
Synergistic effects of ECM and heterotypic crosstalk on cellular responses in non-alcoholic fatty liver disease$593,310
R01 · FY2023 · DK · contact PI
Human iPSC-derived atrial cardiomyocytes to model atrial fibrillation in a dish$587,809
R01 · FY2023 · HL
A bio-engineered hepatic niche for ex vivo expansion of HSCs$319,800
R01 · FY2023 · HL
Multicellular Organotypic Mouse Model of Alcoholic Liver Disease$242,942
R21 · FY2023 · AA · contact PI
Human iPSC-derived atrial cardiomyocytes to model atrial fibrillation in a dish$595,804
R01 · FY2022 · HL
A bio-engineered hepatic niche for ex vivo expansion of HSCs$319,800
R01 · FY2022 · HL
Biofabrication of Multicompartment Human Liver Tissues for Chemical Screening$194,533
R21 · FY2022 · ES
Human iPSC-derived atrial cardiomyocytes to model atrial fibrillation in a dish$26,016
R01 · FY2022 · HL
Human iPSC-derived atrial cardiomyocytes to model atrial fibrillation in a dish$704,949
R01 · FY2021 · HL
Elucidating chemo-mechanical determinants of human hepatocyte and stellate cell responses in non-alcoholic fatty liver disease$344,492
R01 · FY2021 · DK · contact PI
A bio-engineered hepatic niche for ex vivo expansion of HSCs$319,800
R01 · FY2021 · HL
Biofabrication of Multicompartment Human Liver Tissues for Chemical Screening$234,664
R21 · FY2021 · ES
Human iPSC-derived atrial cardiomyocytes to model atrial fibrillation in a dish$659,665
R01 · FY2020 · HL
Elucidating chemo-mechanical determinants of human hepatocyte and stellate cell responses in non-alcoholic fatty liver disease$344,894
R01 · FY2020 · DK · contact PI
A Scalable 3D Human Liver Co-culture Platform for Hepatitis B Virus Infection$185,726
R21 · FY2020 · AI · contact PI
High-throughput exploration of chemomechanical crosstalk in the maturation of iPSC-derived human hepatocytes$184,392
R21 · FY2020 · ES · contact PI
Elucidating chemo-mechanical determinants of human hepatocyte and stellate cell responses in non-alcoholic fatty liver disease$69,750
R01 · FY2020 · DK · contact PI
Human iPSC-derived atrial cardiomyocytes to model atrial fibrillation in a dish$19,268
R01 · FY2020 · HL
Elucidating chemo-mechanical determinants of human hepatocyte and stellate cell responses in non-alcoholic fatty liver disease$345,284
R01 · FY2019 · DK · contact PI
A Scalable 3D Human Liver Co-culture Platform for Hepatitis B Virus Infection$240,966
R21 · FY2019 · AI · contact PI
High-throughput exploration of chemomechanical crosstalk in the maturation of iPSC-derived human hepatocytes$224,632
R21 · FY2019 · ES · contact PI
Elucidating chemo-mechanical determinants of human hepatocyte and stellate cell responses in non-alcoholic fatty liver disease$345,664
R01 · FY2018 · DK · contact PI
Functionally maturing iPSC-derived human hepatocytes in 3D microgels$185,971
R21 · FY2018 · ES · contact PI
Functionally maturing iPSC-derived human hepatocytes in 3D microgels$240,624
R21 · FY2017 · ES · contact PI
Exploring HCV infection in engineered cultures of iPSC-derived human liver cells$79,921
R03 · FY2016 · AI · contact PI
Engineering zonal human liver functions in vitro using microfluidics$90,743
R03 · FY2015 · EB · contact PI
Exploring HCV infection in engineered cultures of iPSC-derived human liver cells$48,645
R03 · FY2015 · AI · contact PI
Exploring HCV infection in engineered cultures of iPSC-derived human liver cells$26,958
R03 · FY2015 · AI · contact PI
Engineering zonal human liver functions in vitro using microfluidics$81,719
R03 · FY2014 · EB · contact PI
Towards a Miniaturized Human Liver Array for High-throughput Screening$410,200
RC1 · FY2010 · AA · contact PI
Micro-Liver Platform Development for Evaluating Drug Disposition and Toxicity In$113,044
R44 · FY2010 · FD · contact PI
Towards a Miniaturized Human Liver Array for High-throughput Screening$499,800
RC1 · FY2009 · AA · contact PI
Evaluating drug metabolism and drug-drug interactions in a microscale model of hu$100,000
R43 · FY2008 · FD · contact PI